BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Cardiovascular Disease / Dyslipidemia readouts · AssetMemo
X-WR-CALDESC:Upcoming phase 1/2 and later readouts in Cardiovascular Diseas
 e / Dyslipidemia\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05464784-8091@assetmemo.bio
DTSTAMP:20261121T005020Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Tipelukast: Phase 2 readout est. (NCT05464784)
DESCRIPTION:Tipelukast\, phase 2\, Type 2 Diabetes.\nStudy: MN-001 in Non-a
 lcoholic Fatty Liver Disease\, Type 2 Diabetes Mellitus\, and Hypertriglyc
 eridemia\nEstimated primary completion: 31 December 2026. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/tipelukast#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT05464784
URL:https://assetmemo.bio/drug/tipelukast#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07587788-1088@assetmemo.bio
DTSTAMP:20261121T005020Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:RBD5044: Phase 2 readout est. (NCT07587788)
DESCRIPTION:RBD5044\, phase 2\, Hypertriglyceridemia.\nStudy: RBD5044 in Ch
 inese Participants With Hypertriglyceridemia\nEstimated primary completion
 : March 2027. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/rbd5044
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT075
 87788
URL:https://assetmemo.bio/drug/rbd5044#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05681351-1044@assetmemo.bio
DTSTAMP:20261121T005020Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Tryngolza (Olezarsen): Phase 3 readout est. (NCT05681351)
DESCRIPTION:Tryngolza (Olezarsen)\, phase 3\, Severe Hypertriglyceridemia.\
 nStudy: CORE-OLE: A Study of Olezarsen (ISIS 678354) Administered Subcutan
 eously to Participants With Severe Hypertriglyceridemia (SHTG)\nEstimated 
 primary completion: March 2027. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/olezarsen#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT05681351
URL:https://assetmemo.bio/drug/olezarsen#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06797401-1088@assetmemo.bio
DTSTAMP:20261121T005020Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:RBD5044: Phase 2 readout est. (NCT06797401)
DESCRIPTION:RBD5044\, phase 2\, Hypertriglyceridemia.\nStudy: Phase 2 Trial
  Evaluating the Efficacy and Safety of RBD5044 in Patients With Mixed Dysl
 ipidemia\nEstimated primary completion: 31 May 2027. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/rbd5044#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT06797401
URL:https://assetmemo.bio/drug/rbd5044#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07308392-1208@assetmemo.bio
DTSTAMP:20261121T005020Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:HRS-7249: Phase 2 readout est. (NCT07308392)
DESCRIPTION:HRS-7249\, phase 2\, Severe Hypertriglyceridemia.\nStudy: Phase
  II Clinical Trial Evaluating the Efficacy and Safety of HRS-7249 and SHR-
 1918 in Patients With Severe Hypertriglyceridemia at High Risk of Acute Pa
 ncreatitis\nEstimated primary completion: June 2027. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/hrs-7249#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT07308392
URL:https://assetmemo.bio/drug/hrs-7249#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07604974-1085@assetmemo.bio
DTSTAMP:20261121T005020Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:ION775: Phase 2 readout est. (NCT07604974)
DESCRIPTION:ION775\, phase 2\, Severe Hypertriglyceridemia.\nStudy: A Study
  to Assess the Safety\, Tolerability and Efficacy of ION775\nEstimated pri
 mary completion: September 2027. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/ion775#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07604974
URL:https://assetmemo.bio/drug/ion775#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07799129-1092@assetmemo.bio
DTSTAMP:20261121T005020Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:EDP167: Phase 2 readout est. (NCT07799129)
DESCRIPTION:EDP167\, phase 2\, Atherosclerotic Cardiovascular Disease.\nStu
 dy: Phase 2 Dose-Finding Study Evaluating the Efficacy and Safety of EDP16
 7 in Adults With Mixed Dyslipidemia\nEstimated primary completion: Novembe
 r 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/edp167#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07799129
URL:https://assetmemo.bio/drug/edp167#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07028749-1200@assetmemo.bio
DTSTAMP:20261121T005020Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:MAR001: Phase 2 readout est. (NCT07028749)
DESCRIPTION:MAR001\, phase 2\, Hypertriglyceridemia.\nStudy: Study of MAR00
 1 in Adults With Elevated Triglycerides and Remnant Cholesterol\nEstimated
  primary completion: November 2027. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/mar001#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT07028749
URL:https://assetmemo.bio/drug/mar001#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07474649-5401@assetmemo.bio
DTSTAMP:20261121T005020Z
DTSTART;VALUE=DATE:20280601
DTEND;VALUE=DATE:20280602
SUMMARY:Rosuvastatin: Phase 3 readout est. (NCT07474649)
DESCRIPTION:Rosuvastatin\, phase 3\, Atherosclerotic Cardiovascular Disease
 .\nStudy: A Study of Bempedoic Acid/Ezetimibe/High-intensity Statin in Pat
 ients Without Cardiovascular Events\nEstimated primary completion: 1 June 
 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/rosuvastatin#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT074746
 49
URL:https://assetmemo.bio/drug/rosuvastatin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06822790-1043@assetmemo.bio
DTSTAMP:20261121T005020Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Redemplo (Plozasiran): Phase 3 readout est. (NCT06822790)
DESCRIPTION:Redemplo (Plozasiran)\, phase 3\, Hypertriglyceridemia.\nStudy:
  Long-Term Safety and Efficacy of Plozasiran in Adults With Hypertriglycer
 idemia\nEstimated primary completion: July 2028. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/plozasiran#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT06822790
URL:https://assetmemo.bio/drug/plozasiran#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07799688-1208@assetmemo.bio
DTSTAMP:20261121T005020Z
DTSTART;VALUE=DATE:20281015
DTEND;VALUE=DATE:20281016
SUMMARY:HRS-7249: Phase 2 readout est. (NCT07799688)
DESCRIPTION:HRS-7249\, phase 2\, Hypertriglyceridemia.\nStudy: A Extension 
 Study to Evaluate the Safety and Efficacy of HRS-7249 in Patients With Hyp
 ertriglyceridemia\nEstimated primary completion: 15 October 2028. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/hrs-7249#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT07799688
URL:https://assetmemo.bio/drug/hrs-7249#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06880770-1043@assetmemo.bio
DTSTAMP:20261121T005020Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:Redemplo (Plozasiran): Phase 3 readout est. (NCT06880770)
DESCRIPTION:Redemplo (Plozasiran)\, phase 3\, Severe Hypertriglyceridemia.\
 nStudy: Study of Plozasiran in Adults With Severe Hypertriglyceridemia at 
 Risk of Acute Pancreatitis\nEstimated primary completion: March 2029. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/plozasiran#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT06880770
URL:https://assetmemo.bio/drug/plozasiran#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
